ZTS
Bearish signalScored 2026-08-03 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Zoetis Inc.
- Nom
- Zoetis Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NYSE
- Capitalisation
- $33.4B
- Employés
- 14,500
- PDG
- Kristin C. Peck
- Site web
- https://www.zoetis.com
- Marché
- ELANIDXXMRKNEOGPAHC
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-19 22:33:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-18 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-07 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-09-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-09-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-17 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-07-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-06-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-09 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2026-06-09 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2026-06-09 | Chuck Fleischmann | Purchase | $15,001 - $50,000 |
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-14 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-03-13 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-01-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-12-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-06 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-08-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-17 | Jefferson Shreve | Sale (Partial) | $15,001 - $50,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-01 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-03-27 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2025-03-05 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-03 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2024-12-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-07-05 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2024-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2024-01-09 | Richard Ray Larsen | Purchase | $1,001 - $15,000 |
| 2023-12-28 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-07-21 | Robert J. Wittman | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-06-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-03-07 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-20 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-26 | Alan Lowenthal | Purchase | $15,001 - $50,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-28 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-04 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-05-04 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-03-08 | Daniel Milton Newhouse | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-26 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-01-26 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-01-21 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-08-03 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
ZTS presents solid financial foundations — strong liquidity (85) and positive fundamental trends (75) — but rising leverage and a lengthening operating cycle introduce meaningful balance sheet risk.
The first sentence of the analysis written for ZTS on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 3.03 · operating margin 38%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.5% | 69.1% | 68.3% | 67.8% | 68.3% | |
| Ebit Margin | 37.8% | 36.5% | 37.4% | 35.8% | 35.0% | |
| Ebitda Margin | 43.0% | 41.8% | 43.1% | 41.6% | 40.8% | |
| Operating Profit Margin | 38.0% | 36.6% | 35.9% | 36.2% | 36.0% | |
| Pretax Profit Margin | 35.5% | 33.8% | 34.4% | 32.9% | 32.0% | |
| Continuous Operations Profit Margin | 28.2% | 27.0% | 27.4% | 26.1% | 26.2% | |
| Net Profit Margin | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | |
| Bottom Line Profit Margin | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | |
| Current Ratio | 3.028 | 1.754 | 3.358 | 2.370 | 3.856 | |
| Quick Ratio | 1.941 | 1.079 | 2.001 | 1.630 | 2.786 | |
| Solvency Ratio | 0.260 | 0.315 | 0.305 | 0.245 | 0.266 | |
| Cash Ratio | 1.034 | 0.582 | 1.079 | 1.129 | 1.938 | |
| Price To Earnings Ratio | 20.866 | 29.786 | 38.852 | 32.494 | 56.883 | |
| Price To Earnings Growth Ratio | 2.038 | 3.880 | 3.074 | 6.336 | 2.302 | |
| Forward Price To Earnings Growth Ratio | 2.038 | 3.880 | 3.074 | 6.336 | 2.302 | |
| Price To Earnings Diluted Ratio | 20.900 | 29.786 | 38.929 | 32.639 | 57.150 | |
| Price To Earnings Diluted Growth Ratio | 2.079 | 3.775 | 3.014 | 6.335 | 2.299 | |
| Price To Book Ratio | 16.750 | 15.514 | 18.215 | 15.600 | 25.480 | |
| Price To Sales Ratio | 5.894 | 7.995 | 10.653 | 8.504 | 14.886 | |
| Price To Free Cash Flow Ratio | 24.439 | 32.203 | 56.151 | 51.822 | 66.679 | |
| Price To Operating Cash Flow Ratio | 19.213 | 25.060 | 38.683 | 35.939 | 52.307 | |
| Debt To Assets Ratio | 0.614 | 0.474 | 0.473 | 0.542 | 0.485 | |
| Debt To Equity Ratio | 2.850 | 1.414 | 1.352 | 1.837 | 1.484 | |
| Debt To Capital Ratio | 0.740 | 0.586 | 0.575 | 0.647 | 0.597 | |
| Long Term Debt To Capital Ratio | 0.735 | 0.523 | 0.568 | 0.598 | 0.592 | |
| Financial Leverage Ratio | 4.643 | 2.985 | 2.859 | 3.388 | 3.060 | |
| Working Capital Turnover Ratio | 2.664 | 2.634 | 1.943 | 1.706 | 1.624 | |
| Operating Cash Flow Ratio | 1.299 | 0.865 | 1.246 | 0.604 | 1.231 | |
| Operating Cash Flow Sales Ratio | 0.307 | 0.319 | 0.275 | 0.237 | 0.285 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.786 | 0.778 | 0.689 | 0.694 | 0.784 | |
| Debt Service Coverage Ratio | 11.426 | 2.032 | 11.835 | 1.770 | 11.517 | |
| Interest Coverage Ratio | 14.802 | 14.017 | 11.895 | 12.354 | 11.877 | |
| Short Term Operating Cash Flow Coverage Ratio | 54.792 | 2.187 | 784.333 | 1.414 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.306 | 0.438 | 0.348 | 0.236 | 0.328 | |
| Capital Expenditure Coverage Ratio | 4.676 | 4.508 | 3.214 | 3.263 | 4.639 | |
| Dividend Paid And Capex Coverage Ratio | 1.923 | 2.049 | 1.652 | 1.597 | 2.327 | |
| Dividend Payout Ratio | 0.333 | 0.316 | 0.295 | 0.289 | 0.233 | |
| Enterprise Value Multiple | 15.477 | 20.341 | 25.980 | 21.807 | 37.521 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.5% | ▲1.4% | ▲1.7% |
| Ebit Margin | 37.8% | ▲1.4% | ▲1.3% |
| Ebitda Margin | 43.0% | ▲1.1% | ▲0.9% |
| Operating Profit Margin | 38.0% | ▲1.4% | ▲1.4% |
| Pretax Profit Margin | 35.5% | ▲1.6% | ▲1.8% |
| Continuous Operations Profit Margin | 28.2% | ▲1.3% | ▲1.3% |
| Net Profit Margin | 28.2% | ▲1.4% | ▲1.3% |
| Bottom Line Profit Margin | 28.2% | ▲1.4% | ▲1.3% |
| Current Ratio | 3.028 | ▲1.274 | ▲0.155 |
| Quick Ratio | 1.941 | ▲0.862 | ▲0.054 |
| Solvency Ratio | 0.260 | ▼-0.055 | ▼-0.018 |
| Cash Ratio | 1.034 | ▲0.453 | ▼-0.118 |
| Price To Earnings Ratio | 20.866 | ▼-8.920 | ▼-14.911 |
| Price To Earnings Growth Ratio | 2.038 | ▼-1.842 | ▼-1.488 |
| Forward Price To Earnings Growth Ratio | 2.038 | ▼-1.842 | ▼-1.488 |
| Price To Earnings Diluted Ratio | 20.900 | ▼-8.886 | ▼-14.981 |
| Price To Earnings Diluted Growth Ratio | 2.079 | ▼-1.697 | ▼-1.422 |
| Price To Book Ratio | 16.750 | ▲1.236 | ▼-1.562 |
| Price To Sales Ratio | 5.894 | ▼-2.102 | ▼-3.693 |
| Price To Free Cash Flow Ratio | 24.439 | ▼-7.764 | ▼-21.820 |
| Price To Operating Cash Flow Ratio | 19.213 | ▼-5.847 | ▼-15.028 |
| Debt To Assets Ratio | 0.614 | ▲0.140 | ▲0.096 |
| Debt To Equity Ratio | 2.850 | ▲1.436 | ▲1.063 |
| Debt To Capital Ratio | 0.740 | ▲0.154 | ▲0.111 |
| Long Term Debt To Capital Ratio | 0.735 | ▲0.212 | ▲0.132 |
| Financial Leverage Ratio | 4.643 | ▲1.659 | ▲1.256 |
| Working Capital Turnover Ratio | 2.664 | ▲0.030 | ▲0.550 |
| Operating Cash Flow Ratio | 1.299 | ▲0.434 | ▲0.250 |
| Operating Cash Flow Sales Ratio | 0.307 | ▼-0.012 | ▲0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.786 | ▲0.008 | ▲0.040 |
| Debt Service Coverage Ratio | 11.426 | ▲9.394 | ▲3.710 |
| Interest Coverage Ratio | 14.803 | ▲0.786 | ▲1.813 |
| Short Term Operating Cash Flow Coverage Ratio | 54.792 | ▲52.605 | ▼-113.753 |
| Operating Cash Flow Coverage Ratio | 0.306 | ▼-0.132 | ▼-0.025 |
| Capital Expenditure Coverage Ratio | 4.676 | ▲0.168 | ▲0.616 |
| Dividend Paid And Capex Coverage Ratio | 1.923 | ▼-0.126 | ▲0.013 |
| Dividend Payout Ratio | 0.333 | ▲0.016 | ▲0.039 |
| Enterprise Value Multiple | 15.477 | ▼-4.865 | ▼-8.749 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $55.79B | $74.00B | $91.02B | $68.72B | $115.76B | |
| Enterprise value | $62.97B | $78.76B | $95.74B | $73.23B | $119.02B | |
| EV / Sales | 6.65x | 8.51x | 11.21x | 9.06x | 15.31x | |
| EV / Op. cash flow | 21.69x | 26.67x | 40.69x | 38.30x | 53.78x | |
| EV / Free cash flow | 27.58x | 34.27x | 59.06x | 55.23x | 68.56x | |
| EV / EBITDA | 15.48x | 20.34x | 25.98x | 21.81x | 37.52x | |
| Net debt / EBITDA | 1.76x | 1.23x | 1.28x | 1.34x | 1.03x | |
| Current ratio | 3.03x | 1.75x | 3.36x | 2.37x | 3.86x | |
| Income quality | 1.09x | 1.18x | 1.00x | 0.91x | 1.09x | |
| Graham number | $32 | $36 | $35 | $31 | $30 | |
| Graham net-net | -$17 | -$12 | -$11 | -$10 | -$9 | |
| Tax burden | 79.6% | 79.3% | 79.8% | 79.6% | 81.9% | |
| Interest burden | 93.8% | 92.8% | 91.9% | 91.8% | 91.3% | |
| Working capital | $4.53B | $2.57B | $4.45B | $4.34B | $5.13B | |
| Invested capital | $12.27B | $10.04B | $11.98B | $11.44B | $11.89B | |
| Return on assets | 17.3% | 17.5% | 16.4% | 14.2% | 14.7% | |
| Operating ROA | 24.2% | 23.8% | 21.0% | 20.3% | 20.4% | |
| Return on tangible assets | 22.8% | 23.9% | 23.0% | 19.6% | 20.9% | |
| Return on equity | 80.2% | 52.1% | 46.9% | 48.0% | 44.8% | |
| Return on invested capital | 21.5% | 22.2% | 19.7% | 17.8% | 18.9% | |
| Return on capital employed | 27.2% | 31.3% | 24.8% | 24.9% | 23.2% | |
| Earnings yield | 4.8% | 3.4% | 2.6% | 3.1% | 1.8% | |
| Free cash flow yield | 4.1% | 3.1% | 1.8% | 1.9% | 1.5% | |
| Capex / Op. cash flow | 21.4% | 22.2% | 31.1% | 30.6% | 21.6% | |
| Capex / Depreciation | 127.5% | 131.8% | 149.1% | 126.0% | 106.5% | |
| Capex / Sales | 6.6% | 7.1% | 8.6% | 7.3% | 6.1% | |
| SG&A / Sales | 25.1% | 25.0% | 25.2% | 24.9% | 25.7% | |
| R&D / Sales | 7.4% | 7.4% | 7.2% | 6.7% | 6.5% | |
| Stock comp / Sales | 0.9% | 0.8% | 0.7% | 0.8% | 0.7% | |
| Intangibles / Total assets | 24.3% | 27.0% | 28.7% | 27.6% | 29.9% | |
| Days sales outstanding | 61d | 52d | 56d | 55d | 53d | |
| Days payables outstanding | 64d | 55d | 55d | 57d | 65d | |
| Operating cycle | 379d | 346d | 401d | 384d | 338d | |
| Cash conversion cycle | 315d | 291d | 346d | 327d | 273d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-17 8,293 Zoetis Inc. $ZTS Shares Sold by Banque Pictet & Cie SA Banque Pictet and Cie SA reduced its holdings in shares of Zoetis Inc. (NYSE: ZTS) by 0.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,785,312 shares of the company''s stock after selling 8,293 shares during the quarter.
- 2026-10-13 Zoetis Appoints Iris Knobloch to its Board of Directors PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of.
- 2026-10-11 10 Dividend Growth Stocks: October 2026 In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This month''s screen targets dividend growth stocks with Dividend Safety scores ≥8.0, forward yields ≥2.5%, and prices at or below fair value. An equally weighted portfolio of the top 10 stocks yields 2.8% but would have underperformed SPY over the past 5 years.
- 2026-10-11 Top 50 High-Quality Dividend Growth Stocks For October 2026 I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.
- 2026-10-09 Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.
- 2026-10-09 A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I''m Buying Right Now Whether you want a higher 3% dividend yield or a quickly growing dividend that yields 1.2%, these two stocks look like rare opportunities.
- 2026-10-08 Zoetis Declares Fourth Quarter 2026 Dividend PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company''s common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world''s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a leg.
- 2026-10-06 New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1 PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today''s heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data th.
- 2026-10-05 40,294 Zoetis Inc. $ZTS Shares Purchased by Rockland Trust Co. Rockland Trust Co. boosted its stake in Zoetis Inc. (NYSE: ZTS) by 19.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 244,065 shares of the company''s stock after buying an additional 40,294 shares during the quarter. Rockland Trust Co. owned approximately 0.06%
- 2026-10-01 Zoetis (ZTS) Stock Sinks As Market Gains: Here''s Why Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.